4th Jun 2021 12:26
Ap19
FORM 8.3 Amendment to purchase
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
| Name of person dealing (Note 1) | Barclays PLC. | |
| Company dealt in | WILLIS TOWERS WATSON PLC | |
| Class of relevant security to which the | ORD | |
| dealings being disclosed relate (Note 2) | ||
| Date of dealing | 02 June 2021 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
| Class of relevant security: | ORD | ||||
Long | Short | ||||
Number | (%) | Number | (%) | ||
(1) | Relevant securities |
|
|
|
|
1,878,738 | 1.46% | 230,964 | 0.18% | ||
|
|
|
| ||
(2) | Derivatives (other than options): |
|
|
|
|
72,359 | 0.06% | 94,581 | 0.07% | ||
|
|
|
| ||
(3) | Options and agreements to |
|
|
|
|
| purchase/sell: | 6,100 | 0.00% | 6,100 | 0.00% | |
|
|
|
| ||
| TOTAL: |
|
|
|
| |
1,957,197 | 1.52% | 331,645 | 0.26% | ||
|
|
|
| ||
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
Class of relevant security: | Long | Short | ||||
| Number |
| (%) | Number |
| (%) |
(1) Relevant securities |
|
| ||||
(2) Derivatives (other than options) |
|
| ||||
(3) Options and agreements to purchase/sell |
|
| ||||
Total |
|
| ||||
| ||||||
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale | Number of relevant securities | Price per unit |
Purchase | 10 | 259.2170 USD |
Purchase | 38 | 260.7100 USD |
Purchase | 51 | 260.2200 USD |
Purchase | 62 | 259.7700 USD |
Purchase | 99 | 259.1791 USD |
Purchase | 101 | 261.3341 USD |
Purchase | 107 | 260.1604 USD |
Purchase | 143 | 259.9999 USD |
Purchase | 144 | 260.8880 USD |
Purchase | 172 | 260.8543 USD |
Purchase | 200 | 260.8600 USD |
Purchase | 200 | 258.7300 USD |
Purchase | 218 | 260.0470 USD |
Purchase | 220 | 260.1681 USD |
Purchase | 281 | 260.0867 USD |
Purchase | 365 | 260.0741 USD |
Purchase | 462 | 258.7835 USD |
Purchase | 580 | 260.1594 USD |
Purchase | 600 | 259.6133 USD |
Purchase | 635 | 260.7069 USD |
Purchase | 910 | 260.0546 USD |
Purchase | 1,721 | 259.7190 USD |
Purchase | 1,758 | 258.7019 USD |
Purchase | 1,978 | 260.7291 USD |
Purchase | 2,400 | 260.1990 USD |
Purchase | 4,602 | 259.8903 USD |
Purchase | 4,955 | 258.6100 USD |
Purchase | 5,880 | 258.8090 USD |
Purchase | 9,246 | 260.3103 USD |
Purchase | 10,451 | 260.3774 USD |
Purchase | 11,121 | 260.7880 USD |
Purchase | 11,580 | 260.5388 USD |
Purchase | 22,465 | 259.4440 USD |
Sale | 1 | 260.0900 USD |
Sale | 2 | 261.6450 USD |
Sale | 4 | 261.0800 USD |
Sale | 4 | 260.8500 USD |
Sale | 20 | 260.0350 USD |
Sale | 30 | 260.1700 USD |
Sale | 43 | 260.6518 USD |
Sale | 47 | 260.0427 USD |
Sale | 62 | 259.7700 USD |
Sale | 68 | 261.1000 USD |
Sale | 98 | 259.1698 USD |
Sale | 100 | 260.0200 USD |
Sale | 100 | 260.1500 USD |
Sale | 106 | 260.6993 USD |
Sale | 133 | 260.1327 USD |
Sale | 144 | 260.8880 USD |
Sale | 200 | 259.5000 USD |
Sale | 238 | 259.3000 USD |
Sale | 400 | 260.2200 USD |
Sale | 470 | 260.2348 USD |
Sale | 480 | 261.3354 USD |
Sale | 950 | 260.3142 USD |
Sale | 1,200 | 260.1990 USD |
Sale | 1,341 | 260.9430 USD |
Sale | 2,484 | 259.2936 USD |
Sale | 4,137 | 260.4126 USD |
Sale | 5,089 | 260.2283 USD |
Sale | 6,312 | 259.9184 USD |
Sale | 6,358 | 259.3960 USD |
Sale | 6,797 | 260.2704 USD |
Sale | 10,614 | 258.6100 USD |
Sale | 10,634 | 260.7985 USD |
Sale | 16,472 | 260.5211 USD |
Sale | 19,073 | 259.4803 USD |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (Note 5) |
|
|
|
|
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
|
|
|
|
|
|
|
(ii) Exercising
Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None
| Is a Supplemental Form 8 (Open Positions) attached? | YES |
| Date of disclosure: | 4 Jun 2021 |
| Contact name: | Large Holdings Regulatory Operations |
| Telephone number: | 020 3134 7213 |
| If a connected EFM, name of offeree/offeror with which connected | |
| If a connected EFM, state nature of connection |
|
Ap23
SUPPLEMENTAL FORM 8
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DETAILS OF OPEN POSITIONS
(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)
OPEN POSITIONS (Note 1)
Product name | Written or | Number of | Exercise | Type | Expiry |
| purchased | relevant securities | price |
| date |
|
| to which the option |
|
|
|
|
| or derivative |
|
|
|
|
| relates |
|
|
|
Put Options | Purchased | -100 | 220.0000 | American | Jul 16, 2021 |
Call Options | Purchased | 100 | 240.0000 | American | Jul 16, 2021 |
Call Options | Purchased | 6,000 | 220.0000 | American | Jul 16, 2021 |
Put Options | Purchased | -6,000 | 200.0000 | American | Jul 16, 2021 |
Notes
1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.
2. For all prices and other monetary amounts, the currency must be stated.
For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210604005305/en/
Copyright Business Wire 2021
Related Shares:
Barclays